BR112023001621A2 - Métodos de tratamento de neuralgia trigeminal - Google Patents

Métodos de tratamento de neuralgia trigeminal

Info

Publication number
BR112023001621A2
BR112023001621A2 BR112023001621A BR112023001621A BR112023001621A2 BR 112023001621 A2 BR112023001621 A2 BR 112023001621A2 BR 112023001621 A BR112023001621 A BR 112023001621A BR 112023001621 A BR112023001621 A BR 112023001621A BR 112023001621 A2 BR112023001621 A2 BR 112023001621A2
Authority
BR
Brazil
Prior art keywords
trigeminal neuralgia
treatment methods
neuralgia treatment
methods
individual
Prior art date
Application number
BR112023001621A
Other languages
English (en)
Portuguese (pt)
Inventor
Garibaldi George
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of BR112023001621A2 publication Critical patent/BR112023001621A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
BR112023001621A 2020-07-30 2021-07-30 Métodos de tratamento de neuralgia trigeminal BR112023001621A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30
PCT/EP2021/071376 WO2022023519A1 (en) 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia

Publications (1)

Publication Number Publication Date
BR112023001621A2 true BR112023001621A2 (pt) 2023-04-04

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001621A BR112023001621A2 (pt) 2020-07-30 2021-07-30 Métodos de tratamento de neuralgia trigeminal

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2011035209A1 (en) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Also Published As

Publication number Publication date
TW202220649A (zh) 2022-06-01
EP4188370A1 (en) 2023-06-07
CN115989024A (zh) 2023-04-18
AU2021316675A1 (en) 2023-01-19
CL2023000261A1 (es) 2023-09-08
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CO2018012099A2 (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
BR112018075947A2 (pt) composições de revestimento
PH12017500513A1 (en) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
CO2023004195A2 (es) Compuestos heterocíclicos
PH12021551317A1 (en) Modulators of trex1
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
BR112022021562A2 (pt) Partículas interferentes terapêuticas para o coronavírus
NZ754372A (en) Heterocyclic modulators of lipid synthesis
BR112022001054A2 (pt) Inibidores enzimáticos
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
SG11201811536PA (en) Composition for removing sulfur-containing compound
MX2021015873A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
EA201991988A1 (ru) Композиции и способы для способствования росту волос с помощью ингибиторов mpc1
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
BR112022024760A2 (pt) Métodos de tratamento do complexo de esclerose tuberosa
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
BR112023001621A2 (pt) Métodos de tratamento de neuralgia trigeminal
PH12023553004A1 (en) Modulators of trex1
CR20230157A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme
BR112022017725A2 (pt) Composto 67a inibidor de rad51 (2301085-06-1) em uma dosagem específica para o tratamento de câncer
CR20230542A (es) Moduladores de trex1